Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CSL 346

Next Previous
X
Search
Drug Profile

CSL 346

Alternative Names: 2H10; CSL-346

Latest Information Update: 17 Nov 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Zenyth Therapeutics
  • Developer CSL; Zenyth Therapeutics
  • Class Antihyperglycaemics; Monoclonal antibodies
  • Mechanism of Action Fatty acid modulators; Vascular endothelial growth factor B inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Diabetic nephropathies
  • No development reported Type 2 diabetes mellitus
  • Discontinued Cancer; Rheumatoid arthritis

Most Recent Events

  • 24 Oct 2022 CSL Behring completes a phase IIa trial in Diabetic nephropathies in USA, Australia, Canada, Israel, New Zealand and Puerto Rico (IV, SC) (NCT04419467)
  • 28 Mar 2021 No recent reports of development identified for preclinical development in Diabetic-nephropathies in Australia (SC, Injection)
  • 28 Dec 2020 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus(In volunteers) in Australia (IV, Infusion)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top